Organization
Calico Life Sciences
9 clinical trials
Clinical trial
A Phase 1, Multi-center, Open Label First-in-Human Study With ABBV-CLS-484 Alone and in Combination in Subjects With Locally Advanced or Metastatic TumorsStatus: Recruiting, Estimated PCD: 2025-08-18
Clinical trial
A Phase 1 Placebo-and Active-Controlled Crossover Study of the Potential for Cardiac Repolarization Effects Following Single Dose of ABBV-CLS-7262 in Healthy SubjectsStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy Following ABBV-CLS-7262 Administration in Adult and Pediatric Subjects With Vanishing White Matter DiseaseStatus: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
A Phase 1 Study to Evaluate Safety, Tolerability, and Food-Effect Following Administration of ABBV-CLS-7262 in Healthy VolunteersStatus: Completed, Estimated PCD: 2024-01-30
Clinical trial
A Phase 1 Study to Evaluate the Drug-Drug Interaction Between ABBV-CLS-7262, Rosuvastatin, and Digoxin Following Multiple Doses of ABBV-CLS-7262Status: Completed, Estimated PCD: 2023-05-08
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of ABBV-CLS-7262 in Subjects With Amyotrophic Lateral Sclerosis Followed by an Active Treatment ExtensionStatus: Active (not recruiting), Estimated PCD: 2023-01-12
Clinical trial
A Phase 1, Multi-center, Open Label First-in-Human Study With ABBV-CLS-579 Alone and in Combination in Subjects With Locally Advanced or Metastatic TumorsStatus: Recruiting, Estimated PCD: 2025-08-29
Clinical trial
Mass Balance Study of [14C] ABBV-CLS-7262 in Healthy Male Volunteers Following Single Oral Dose AdministrationStatus: Recruiting, Estimated PCD: 2024-07-11